Advancements in AAV Gene Therapy: The Pro10™ Cell Line and its Impact on Large-Scale Manufacturing

A Pro10 Cell Line: Proprietary Mammalian Suspension Technology for Scalable rAAV Production

In this paper, we explore the Pro10™ cell line, a new technology that enhances the efficiency and scalability of recombinant adeno-associated virus (rAAV) production for gene therapy manufacturing. The Pro10™ cell line is a proprietary mammalian suspension technology that enables scalable and robust production of rAAVs, addressing the challenges associated with large-scale manufacturing in AAV gene therapies.

These cells have been fully characterized and licensed for gene therapy development by various biopharmaceutical companies, making them a reliable option for rAAV vector manufacturing. Viralgen utilizes the Pro10™ cells as the core of its platform process for manufacturing AAV vectors. These cells have been optimized specifically for rAAV production and have successfully been scaled up to 2000L, showcasing consistent and reproducible cell growth rates. They are capable of producing various AAV serotypes and have demonstrated similar productivity levels in both small and large-scale bioreactors.

The Pro10™ cells play a critical role in Viralgen’s platform process for manufacturing AAV vectors and have significantly contributed to the production of innovative gene therapies. For more information on the HEK293 derived animal component-free suspension Pro10™ cell line, access our full PDF detailing its properties and benefits.

In this paper, we explore the Pro10™ cell line, a new technology that enhances the efficiency and scalability of recombinant adeno-associated virus (rAAV) production for gene therapy manufacturing. The Pro10™ cell line is a proprietary mammalian suspension technology that enables scalable and robust production of rAAVs, addressing the challenges associated with large-scale manufacturing in AAV…

Leave a Reply